Akademik Veri Yönetim Sistemi
Practical Radiation Oncology, cilt.15, sa.2, ss.120-123, 2025 (SCI-Expanded)
Lorlatinib is a central nervous system-penetrant third-generation tyrosine kinase inhibitor approved for the first-line management of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangement,1 which accounts for 3% to 5% of non-small cell lung cancer cases.2 The most commonly reported side effects include hyperlipidemia, edema, peripheral neuropathy, and central nervous system effects.2 Whereas ocular side effects such as photopsia, blurred vision, vitreous floaters, and diplopia have been documented with another anaplastic lymphoma kinase-tyrosine kinase inhibitor, crizotinib, there are few reports of such effects with lorlatinib.3 Herein, we present a case of bilateral optic neuropathy, initially misdiagnosed as optic nerve metastases and treated with palliative radiation therapy.